Compare BIO-TECHNE Corp (TECH) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Workday Inc — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Workday Inc trades at $181.1 (market cap $45.49B). The key difference: Workday Inc is far larger — about 4× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Workday Inc pays none. Which is the better fit depends on your goals.
| TECH | WDAY | |
|---|---|---|
Market Cap | $11.24B | $45.49B |
Sector | Health | Technology |
52-Week High | $72.29 | $247.69 |
52-Week Low | $43.31 | $112.55 |
Enterprise Value | $11.32B | $44.94B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Workday (WDAY) trades at $179.64, up 5.52% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting an uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, the company has consistently beaten earnings expectations, with Q1 2026 EPS of $2.66 surpassing estimates of $2.51. Revenue growth is robust, projected to rise from $8.45B in 2025 to $9.9B in 2026, though net income margins have fluctuated. Recent news highlights partnerships and product launches, such as the Workday Adaptive Planning FedRAMP authorization announced on July 23, 2026.
The outlook for WDAY is positive, driven by earnings beats and strategic AI integrations, but elevated valuation ratios like a P/E of 55.96 pose risks. Investors should weigh growth potential against competitive pressures and market volatility, with analyst consensus leaning bullish but caution advised near technical resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
